

In the Claims

Please cancel Claims 4, 5, 29 and 30. Please amend Claims 1, 13, 23, 26, 47, 74, 79, 91 and 92. Amendments to the claims are indicated in the attached "Marked Up Version of Amendments" (pages i - ii)

Sub 0¹ C1 1. (Three times amended) A retroviral vector comprising a heterologous gene placed under transcriptional control of a 0.6 Kb PstI MMTV promoter fragment, wherein the MMTV promoter fragment directs expression of the heterologous gene in a cell when the vector is introduced into the cell.

Sub 0² C2 13. (Twice amended) A retroviral provirus carrying a construct comprising a heterologous gene placed under transcriptional control of a 0.6 Kb PstI MMTV promoter fragment.

Sub 0³ C3 23. (Twice amended) A pharmaceutical composition comprising a DNA construct comprising a therapeutic gene placed under transcriptional control of a 0.6 Kb PstI MMTV promoter fragment, and a pharmaceutically acceptable carrier or diluent.

Sub 0⁴ C4 26. (Three times amended) A method for the expression of a heterologous gene in a human cell comprising introducing a retroviral vector comprising said gene under transcriptional control of a 0.6 Kb PstI MMTV promoter fragment into the human cell and maintaining the cell under conditions in which the gene is expressed in the human cell.

C5 47. (Amended) The method according to claim 41 wherein a DNA construct selected from the group consisting of: viral and plasmid vectors, is introduced into the human mammary cell.

Sub D7
74. (Amended) A retroviral vector comprising a heterologous gene placed under transcriptional control of a 0.6 Kb PstI MMTV promoter fragment, wherein the MMTV promoter fragment directs expression of the heterologous gene in a human mammary cell when the vector is introduced into the cell.

Sub D7
79. (Amended) A retroviral provirus carrying a construct comprising a heterologous gene placed under transcriptional control of a 0.6 Kb PstI MMTV promoter fragment.

Sub D8
91. (Amended) A method for the expression of a heterologous gene in a human cell comprising introducing a retroviral vector comprising said gene under transcriptional control of a 0.6 Kb PstI MMTV promoter fragment into the human cell and maintaining the cell under conditions in which the gene is expressed in the human cell.

92. (Amended) A method for the treatment of human mammary carcinoma comprising administering to a human in need thereof a DNA construct comprising a therapeutic gene placed under transcriptional control of a 0.6 Kb PstI MMTV promoter fragment, wherein the therapeutic gene is expressed in human mammary carcinoma cells and the human mammary carcinoma is treated.